EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Metabolic Rewiring in MASLD: From Disease Mechanisms to Precision Medicine

Amedeo Lonardo iD, Ralf Weiskirchen iD

Metabolites · 27.07.2026 · 16 (8) · 529

DOI: 10.3390/metabo16080529 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Metabolites, online erschienen am 27.07.2026. Verfasst von Amedeo Lonardo und 1 weiteren Autor:innen. Beteiligte Einrichtung: Independent Researcher, 41100 Modena, Italy. Die Arbeit nennt 156 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD), a leading cause of chronic liver disease, encompasses a continuum from steatosis to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and hepatocellular carcinoma. This review aimed to synthesize current evidence on how metabolomic, lipidomic, and spatial multi-omic approaches illuminate MASLD pathogenesis and support precision hepatology.

Methods

A structured narrative review was conducted through searches of PubMed, Scopus, and Web of Science, complemented by manual screening of key references. Studies were prioritized when they addressed MASLD biology, metabolic rewiring, lipid remodeling, mitochondrial dysfunction, inflammatory and fibrogenic pathways, gut–liver–adipose crosstalk, biomarker development, or therapeutic monitoring.

Results

The reviewed evidence identifies MASLD as a systemic metabolic disorder shaped by excess lipid flux, enhanced de novo lipogenesis, impaired mitochondrial adaptation, oxidative and endoplasmic reticulum stress, sterile inflammation, and hepatic stellate-cell activation. Recurrent metabolomic signatures include altered amino acid, fatty acids, bile acid, and microbial co-metabolite pathways. Lipidomic studies consistently implicate depletion of protective polyunsaturated fatty acids, lysophosphatidylcholines, and phosphatidylcholines, in association with accumulation of diacylglycerols and ceramides, in the transition from steatosis to MASH and fibrosis. Emerging spatial and multi-omic analyses further resolve cell-specific metabolic niches involving hepatocytes, macrophages, endothelial cells, and stellate cells.

Conclusions

Metabolomics provides a mechanistic and translational bridge between molecular injury, histological progression, and non-invasive risk stratification in MASLD. Future progress requires standardized analytical workflows, longitudinal validation, causal pathway interrogation, and integration with imaging, genetics, microbiome profiling, and treatment-response phenotyping. Clinical implementation will require standardized platforms, transparent metabolite identification, external validation across diverse populations, cost-effectiveness analyses, and regulatory-grade evidence of clinical utility.

Schlagwörter

Stichwörter der Autor:innen

MASHbile acidsbiomarkerscholesterolgut–liver axislipidomicsmitochondriaphospholipidssaturated fatty acidssex differences

Autor:innen und Institutionen

  • Independent Researcher, 41100 Modena, Italy.
  • Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), RWTH University Hospital Aachen, D-52074 Aachen, Germany.

ORCID-Profile: Amedeo Lonardo, Ralf Weiskirchen

Zitieren

APA

Lonardo, A., & Weiskirchen, R. (2026). Metabolic Rewiring in MASLD: From Disease Mechanisms to Precision Medicine. Metabolites, 16(8), 529. https://doi.org/10.3390/metabo16080529

Vancouver

Lonardo A, Weiskirchen R. Metabolic Rewiring in MASLD: From Disease Mechanisms to Precision Medicine. Metabolites. 2026;16(8):529. doi:10.3390/metabo16080529

BibTeX
@article{Lonardo2026,
  author = {Lonardo, Amedeo and Weiskirchen, Ralf},
  title = {Metabolic Rewiring in MASLD: From Disease Mechanisms to Precision Medicine},
  journal = {Metabolites},
  year = {2026},
  volume = {16},
  number = {8},
  pages = {529},
  doi = {10.3390/metabo16080529}
}
Kostenlos starten →